Search
Event-free survival considers other adverse events in addition to mortality. It therefore provides a more complete understanding of the effectiveness and consequences of treatment than standard survival measures, but is rarely reported at the population level for childhood cancer.
Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients alike. Despite advancements in brain cancer research driven by a technological revolution, translating our understanding of glioblastoma pathogenesis into improved clinical outcomes remains a critical unmet need.
Current approaches to staging chronic liver diseases have limited utility for predicting liver cancer risk. Here, we employed single-nucleus RNA sequencing (snRNA-seq) to characterize the cellular microenvironment of healthy and pre-malignant livers using two distinct mouse models.
Optic pathway gliomas (OPGs) are associated with significant risk of visual and endocrine morbidity, but data on long-term outcomes in symptomatic patients is sparse. This study reviews the clinical course, disease progression, survival outcomes and long-term sequelae in pediatric patients with symptomatic OPGs in our institution over three decades.
The Toronto Paediatric Cancer Stage Guidelines are a compendium of staging systems developed to facilitate collection of consistent and comparable data on stage at diagnosis for childhood cancers by cancer registries.
A first of its kind research program at The Kids Research Institute Australia aims to develop new strategies to better treat First Nations children with cancer.
Dr Jessica Buck and Associate Professor Raelene Endersby have been appointed to the prestigious Australian Brain Cancer Mission Expert Advisory Panel.
Despite national and global reports of rising incidences of cancer affecting children and young people, a new analysis has found rates of childhood cancer have remained unchanged over the last 30 years in South Australia and the Northern Territory.
A world-first study involving more than 100 cancer researchers and clinicians across Australia – including from The Kids Research Institute Australia and Perth Children’s Hospital – has shown that precision medicine can significantly improve outcomes for children with high-risk cancer.
Researchers dedicated to developing the first cancer immunotherapy tablet have been boosted by a $374,000 CUREator top-up funding grant.